Svb Leerink restated their market perform rating on shares of Allergan (NYSE:AGN) in a report issued on Thursday morning, BenzingaRatingsTable reports. They currently have a $188.00 price objective on the stock, down from their previous price objective of $217.00.
Other analysts also recently issued reports about the stock. Royal Bank of Canada restated an underperform rating and issued a GBX 215 ($2.81) target price on shares of in a report on Wednesday, June 26th. Sanford C. Bernstein downgraded shares of Allergan from an outperform rating to a market perform rating and set a $166.08 target price on the stock. in a report on Tuesday, July 16th. Raymond James downgraded shares of Allergan from an outperform rating to a market perform rating in a report on Tuesday, June 25th. Cantor Fitzgerald restated an overweight rating and issued a $130.00 target price (up from $116.00) on shares of Zoetis in a report on Wednesday, June 12th. Finally, JPMorgan Chase & Co. restated an overweight rating and issued a GBX 280 ($3.66) target price on shares of in a report on Wednesday, June 19th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of Hold and an average price target of $176.27.
Shares of AGN stock opened at $163.16 on Thursday. The stock has a market cap of $53.48 billion, a PE ratio of 9.74, a P/E/G ratio of 1.53 and a beta of 1.63. Allergan has a 52 week low of $114.27 and a 52 week high of $197.00. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.60 and a current ratio of 0.71. The business has a fifty day moving average of $145.42.
Allergan (NYSE:AGN) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $3.79 EPS for the quarter, topping the consensus estimate of $3.55 by $0.24. Allergan had a negative net margin of 45.94% and a positive return on equity of 8.45%. The business had revenue of $3.60 billion for the quarter, compared to analysts’ expectations of $3.55 billion. During the same quarter in the previous year, the company earned $3.74 EPS. The business’s quarterly revenue was down 2.0% compared to the same quarter last year. On average, research analysts forecast that Allergan will post 16.72 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 13th. Investors of record on Tuesday, August 13th will be issued a dividend of $0.74 per share. This represents a $2.96 annualized dividend and a yield of 1.81%. Allergan’s payout ratio is 17.74%.
A number of large investors have recently modified their holdings of AGN. Liberty Wealth Management LLC grew its holdings in Allergan by 108.8% during the 1st quarter. Liberty Wealth Management LLC now owns 190 shares of the company’s stock valued at $27,000 after purchasing an additional 99 shares during the last quarter. Legacy Bridge LLC bought a new position in Allergan during the 1st quarter valued at about $27,000. Patriot Financial Group Insurance Agency LLC grew its holdings in Allergan by 2,162.5% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 181 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares during the last quarter. Investors Research Corp bought a new position in Allergan during the 1st quarter valued at about $29,000. Finally, Evolution Wealth Advisors LLC bought a new position in Allergan during the 2nd quarter valued at about $30,000. Institutional investors own 80.08% of the company’s stock.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
See Also: What are municipal bonds?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.